(Q42497114)

English

Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 November 2017

Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial (English)

1 reference

Europe PubMed Central

1 November 2017

1 reference

based on heuristic

inferred from title

Federico Piacentini

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27484801%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Maria Vittoria Dieci

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27484801%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Pierfranco Conte

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27484801%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Valentina Guarneri

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27484801%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

author name string

A Prat

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27484801%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

E Tagliafico

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27484801%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

L Paré

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27484801%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

G Ficarra

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27484801%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

G Bisagni

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27484801%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

D G Generali

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27484801%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

publication date

2 August 2016

1 reference

Europe PubMed Central

1 November 2017

Annals of Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27484801%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

27

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27484801%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27484801%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

1867-1873

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27484801%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Supervised risk predictor of breast cancer based on intrinsic subtypes

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Clinical implications of the intrinsic molecular subtypes of breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Inflammatory cell infiltration of tumors: Jekyll or Hyde

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

The immune system and response to HER2-targeted treatment in breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Identifiers

10.1093/ANNONC/MDW262

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27484801%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27484801%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42497114&oldid=1959879989"